Breakthrough ischemic stroke in patients already treated with DOACs presents a major therapeutic dilemma: Clinicians must decide whether to continue the same drug, adjust the dose, switch to another anticoagulant, or add an antiplatelet agent.
Corey Diamond, PharmD